Information for companies wishing to market medicines imported via special permit, named patient
Published:
|
Updated:
Changes
- : https://www.dmp.no/offentlig-finansiering/metodevurdering-av-medisinske-produkter/metodevurdering-av-legemidler/prosjektplaner
The Norwegian Medical Products Agency (NOMA) aims to facilitate a swift transition from unregistered to marketed medicines when companies choose to market medicines that are currently imported via special permit, named patient.
A rapid and smooth transition requires close cooperation between NOMA, major pharmacy wholesalers, and potentially healthcare institutions.
We therefore recommend that companies planning to market medicines currently imported via special permit, named patient, contact the wholesalers and the "Special Permit, Named Patient Team" as early as possible (godkjenningsfritak@dmp.no).